Literature DB >> 2994070

Tangier disease: a disorder of intracellular membrane traffic.

G Schmitz, G Assmann, H Robenek, B Brennhausen.   

Abstract

The interaction of human high density lipoproteins (HDL) with isolated human monocytes from control and Tangier patients was studied in tissue culture experiments. It was observed that normal monocytes, similar to mouse peritoneal macrophages, bind HDL to a cell surface receptor, internalize the bound HDL particles, transport the internalized HDL intracellularly through the cytoplasmic compartment without significant degradation, and ultimately resecrete intact HDL. The cellular interaction of Tangier monocytes with normal HDL was markedly different from control monocytes. HDL binding to Tangier monocytes was moderately increased and cell-associated HDL radioactivity was 6- to 10-fold enhanced in Tangier monocytes. The bulk of the internalized HDL, however, was detected in secondary lysosomes. Only minor amounts of the internalized HDL were resecreted from the Tangier monocytes, and most of this was degraded. These data suggest that the cellular metabolism of HDL is abnormal in Tangier monocytes. It is postulated that Tangier disease may be a disorder of intracellular membrane traffic in which HDL is diverted into the lysosomal compartment and degraded instead of being secreted through its regular transcellular route.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2994070      PMCID: PMC391042          DOI: 10.1073/pnas.82.18.6305

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Apoprotein A metabolism in Tangier disease.

Authors:  G Assmann; A Capurso; E Smootz; U Wellner
Journal:  Atherosclerosis       Date:  1978-08       Impact factor: 5.162

2.  The lipoprotein abnormality in Tangier disease: quantitation of A apoproteins.

Authors:  G Assmann; E Smootz; K Adler; A Capurso; K Oette
Journal:  J Clin Invest       Date:  1977-03       Impact factor: 14.808

Review 3.  UCLA Conference. Monocytes and macrophages: functions and diseases.

Authors:  M J Cline; R I Lehrer; M C Territo; D W Golde
Journal:  Ann Intern Med       Date:  1978-01       Impact factor: 25.391

4.  Discontinuous density gradient separation of human mononuclear leucocytes using Percoll as gradient medium.

Authors:  A J Ulmer; H D Flad
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

5.  Isoproteins of human apolipoprotein A-I demonstrated in plasma and intestinal organ culture.

Authors:  V I Zannis; J L Breslow; A J Katz
Journal:  J Biol Chem       Date:  1980-09-25       Impact factor: 5.157

6.  Tangier disease: defective recombination of a specific Tangier apolipoprotein A-I isoform (pro-apo A-i) with high density lipoproteins.

Authors:  G Schmitz; G Assmann; S C Rall; R W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

7.  Tangier disease: a structural defect in apolipoprotein A-I (apoA-I Tangier).

Authors:  L L Kay; R Ronan; E J Schaefer; H B Brewer
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

8.  Proteolytic processing of human preproapolipoprotein A-I. A proposed defect in the conversion of pro A-I to A-I in Tangier's disease.

Authors:  J I Gordon; H F Sims; S R Lentz; C Edelstein; A M Scanu; A W Strauss
Journal:  J Biol Chem       Date:  1983-03-25       Impact factor: 5.157

9.  Tangier disease. High density lipoprotein deficiency due to defective metabolism of an abnormal apolipoprotein A-i (ApoA-ITangier).

Authors:  E J Schaefer; L L Kay; L A Zech; H B Brewer
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

10.  Reversible accumulation of cholesteryl esters in macrophages incubated with acetylated lipoproteins.

Authors:  M S Brown; J L Goldstein; M Krieger; Y K Ho; R G Anderson
Journal:  J Cell Biol       Date:  1979-09       Impact factor: 10.539

View more
  16 in total

Review 1.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Genetic basis of lipoprotein disorders.

Authors:  J L Breslow
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

Review 3.  Apolipoproteins and metabolism in atherosclerosis.

Authors:  A M Gotto
Journal:  Trans Am Clin Climatol Assoc       Date:  1990

4.  Hepatic ABCA1 deficiency is associated with delayed apolipoprotein B secretory trafficking and augmented VLDL triglyceride secretion.

Authors:  Mingxia Liu; Soonkyu Chung; Gregory S Shelness; John S Parks
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2017-07-08       Impact factor: 4.698

Review 5.  Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL.

Authors:  Vassilis I Zannis; Angeliki Chroni; Monty Krieger
Journal:  J Mol Med (Berl)       Date:  2006-02-25       Impact factor: 4.599

6.  In vivo metabolism of proapolipoprotein A-I in Tangier disease.

Authors:  D Bojanovski; R E Gregg; L A Zech; M S Meng; C Bishop; R Ronan; H B Brewer
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

Review 7.  Intracellular cholesterol and phospholipid trafficking: comparable mechanisms in macrophages and neuronal cells.

Authors:  G Schmitz; E Orsó
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

8.  Apolipoprotein A-I variants. Naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I.

Authors:  A von Eckardstein; H Funke; A Henke; K Altland; A Benninghoven; G Assmann
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

Review 9.  Apolipoprotein genes and atherosclerosis.

Authors:  J L Breslow
Journal:  Clin Investig       Date:  1992-05

Review 10.  Lipoproteins, cholesterol homeostasis and cardiac health.

Authors:  Tyler F Daniels; Karen M Killinger; Jennifer J Michal; Raymond W Wright; Zhihua Jiang
Journal:  Int J Biol Sci       Date:  2009-06-29       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.